Details for Patent: 6,916,802

Which drugs does patent 6,916,802 protect, and when does it expire?

Patent 6,916,802 protects CERDELGA and is included in one NDA.

This patent has eleven patent family members in seven countries.

Summary for Patent: 6,916,802

Title:	Amino ceramide-like compounds and therapeutic methods of use
Abstract:	The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
Inventor(s):	Shayman; James A. (Ann Arbor, MI), Harris; David J. (Lexington, MA), Siegel; Craig (Woburn, MA), Nelson; Carol A. (Westford, MA), Copeland; Diane P. (North Billerica, MA)
Assignee:	Genzyme Corporation (Cambridge, MA) The Regents of the University of Michigan (Ann Arbor, MI)
Application Number:	10/839,497
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,916,802
Patent Claim Types: see list of patent claims	Compound; Use; Composition;

Drugs Protected by US Patent 6,916,802

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme Corp	CERDELGA	eliglustat tartrate	CAPSULE;ORAL	205494-001	Aug 19, 2014	AB	RX	Yes	Yes				Y		TREATMENT OF GAUCHER DISEASE TYPE 1

International Family Members for US Patent 6,916,802

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	5929600
Australia	774960
Brazil	0012318